GLSI - Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

• Greenwich LifeSciences is a stock relatively new to the market and lesser-known, as it became public in September of 2020.
• Not long after, the stock skyrocketed over 1000% on early data that the company's GP2 treatment reduced breast cancer recurrences to zero.
• While this is still a developing story, the company has a Phase III trial dead ahead, which could usher in a new wave of investors.
• Greenwich LifeSciences stock has pulled back almost 60% since last April, which may present buying opportunity for investors with a long-term mindset.
• Insiders have been buying, and with the extension of the lockup period and announcement of a share repurchase program, management seems to be telegraphing big things ahead.

For further details see: